Clinical trials: Bacteraemia
Healthy Volunteers
Vorapaxar in the Human Endotoxemia Model
Vorapaxar is a recently approved protease activated receptor - 1 (PAR-1) inhibitor. Platelet inhibition may also exert positive results on coagulation activation and may beneficially influence the inflammatory response.
- Trial name
- NCT02875028
- Testing
- Vorapaxar, LPS
- Where
- Austria
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Healthy Volunteers, Endotoxemia
Defibrotide in the Human Endotoxemia Model --- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide
Defibrotide is an anti-inflammatory and anti-coagulatory agent approved for treatment of veno-occlusive disease. Although it has been in clinical use for almost 30 years, the exact mechanism of action has never been fully…
- Trial name
- LPS_DF (NCT02876601)
- Testing
- Defibrotide, Lipopolysaccharide
- Where
- Austria
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bernd Jilma
Dysbiosis, Endotoxemia
Gut-level Antiinflammatory Activities of Green Tea in Metabolic Syndrome
This study evaluates dietary green tea extract to improve gut health and inflammation in persons with metabolic syndrome and healthy adults.
- Conditions
- Dysbiosis, Endotoxemia, Metabolic Syndrome, Inflammation
- Trial name
- NCT03973996
- Testing
- Green Tea Extract
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Obesity, Endotoxemia
Dietary Green Tea Confection For Resolving Gut Permeability-Induced Metabolic Endotoxemia In Obese Adults
This study is focused on assessing gastrointestinal-level improvements by which green tea limits metabolic endotoxemia. It is completed in two phases.
- Conditions
- Obesity, Endotoxemia, Inflammation
- Trial name
- NCT03413735
- Testing
- Green Tea Extract
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Infections, Streptococcal
A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants
The primary aim of the study is to demonstrate that an investigational 4-dose presentation of the 10Pn-PD-DiT vaccine with preservative is non-inferior to the licensed presentation of Synflorix (preservative-free) in terms of…
- Trial name
- NCT02447432
- Testing
- Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation), Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation), DTPw-HBV/Hib
- Where
- Bangladesh
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline